DSP Healthcare Fund
The portfolio is tightly positioned for pharmaceutical and biotech exposure, with nearly two-thirds concentrated in that sector and top holdings dominated by established drugmakers and emerging life sciences players. The manager's March rebalancing—trimming IPCA while significantly building Cohance—signals conviction in high-growth, niche biotech names over larger incumbents, suggesting a tilt toward innovation-driven upside. At 65% in top-10 holdings, this is a conviction-heavy fund betting on a narrow set of healthcare winners rather than broad sector diversification.
Portfolio analysis · April 2026
NAV & Returns
| Plan | NAV | 1M | 3M | 6M | 1Y | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|---|---|---|
| Direct Growth | ₹43.9510 | — | — | — | — | — | — |
| Regular Growth | ₹39.3930 | +6.24% | +6.38% | -1.17% | +7.05% | +21.51% | +13.76% |
| Direct IDCW | ₹25.4160 | — | — | — | — | — | — |
| Regular IDCW | ₹22.8190 | — | — | — | — | — | — |
Portfolio Metrics(latest month)
What Changed2026-03-31 → 2026-04-30
| Stock | Weight | |
|---|---|---|
| No new entries this month | ||
Full Holdings
| # | Holding | % to NAV |
|---|---|---|
| 1 | Sun Pharmaceutical Industries Limited INE044A01036 | 8.84% |
| 2 | IPCA Laboratories Limited INE571A01038 | 8.26% |
| 3 | Cipla Limited INE059A01026 | 7.56% |
| 4 | Globus Medical Inc US3795772082 | 7.35% |
| 5 | Laurus Labs Limited INE947Q01028 | 6.42% |
| 6 | Illumina Inc US4523271090 | 6.16% |
| 7 | Sai Life Sciences Limited INE570L01029 | 6.10% |
| 8 | Gland Pharma Limited INE068V01023 | 5.13% |
| 9 | Cohance Lifesciences Limited INE03QK01018 | 4.83% |
| 10 | Apollo Hospitals Enterprise Limited INE437A01024 | 4.73% |
| 11 | Alembic Pharmaceuticals Limited INE901L01018 | 3.43% |
| 12 | Vijaya Diagnostic Centre Limited INE043W01024 | 3.36% |
| 13 | Pfizer Limited INE182A01018 | 3.01% |
| 14 | Kovai Medical Center and Hospital Limited INE177F01017 | 2.97% |
| 15 | Procter & Gamble Health Limited INE199A01012 | 2.64% |
| 16 | Intuitive Surgical Inc US46120E6023 | 2.60% |
| 17 | TREPS / Reverse Repo Investments | 2.19% |
| 18 | Indoco Remedies Limited INE873D01024 | 2.16% |
| 19 | Emcure Pharmaceuticals Limited INE168P01015 | 2.01% |
| 20 | Concord Biotech Limited INE338H01029 | 1.81% |
Sector Allocation
Top 10 sectors by % to NAV. Excludes derivatives.